Rilotumumab (previously AMG102) is a human monoclonal antibody designed for the treatment of solid tumors. Rilotumumab was in development by Amgen, Inc...
3 KB (127 words) - 15:28, 19 May 2023
Volitinib Antibodies: Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF...
121 KB (13,799 words) - 06:42, 1 July 2024
Volitinib Antibodies: Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF...
68 KB (5,993 words) - 00:22, 20 June 2024
Volitinib Antibodies: Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF...
150 KB (15,741 words) - 10:52, 27 June 2024
Volitinib Antibodies: Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF...
31 KB (3,413 words) - 23:30, 21 June 2024
Volitinib Antibodies: Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF...
12 KB (1,049 words) - 10:54, 12 January 2024
Volitinib Antibodies: Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF...
17 KB (1,489 words) - 05:47, 7 April 2024
Volitinib Antibodies: Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF...
10 KB (579 words) - 06:46, 26 June 2024
Volitinib Antibodies: Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF...
92 KB (8,667 words) - 19:29, 28 June 2024
Volitinib Antibodies: Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF...
10 KB (661 words) - 04:10, 26 June 2024
Volitinib Antibodies: Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF...
36 KB (4,822 words) - 06:03, 26 June 2024
Volitinib Antibodies: Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF...
25 KB (2,085 words) - 03:15, 6 July 2024
Volitinib Antibodies: Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF...
14 KB (1,671 words) - 12:47, 23 April 2024
Volitinib Antibodies: Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF...
16 KB (1,784 words) - 04:08, 6 January 2024
Volitinib Antibodies: Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF...
26 KB (2,542 words) - 19:54, 20 March 2024
Volitinib Antibodies: Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF...
34 KB (3,010 words) - 05:48, 22 May 2024
Volitinib Antibodies: Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF...
5 KB (412 words) - 23:17, 19 June 2023
Volitinib Antibodies: Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF...
74 KB (6,565 words) - 05:35, 13 June 2024
In November 2014 the company announced it was halting all trials of rilotumumab in advanced gastric cancer patients after one of the trials found more...
95 KB (7,725 words) - 21:13, 5 July 2024
Volitinib Antibodies: Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF...
23 KB (1,755 words) - 04:41, 3 July 2024
Volitinib Antibodies: Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF...
22 KB (2,133 words) - 06:05, 5 July 2024
Volitinib Antibodies: Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF...
20 KB (1,543 words) - 06:38, 10 March 2024
Volitinib Antibodies: Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF...
24 KB (1,700 words) - 04:21, 2 July 2024
Volitinib Antibodies: Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF...
43 KB (4,776 words) - 13:06, 5 July 2024
Volitinib Antibodies: Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF...
40 KB (4,580 words) - 05:24, 3 June 2024
Volitinib Antibodies: Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF...
110 KB (10,699 words) - 12:57, 17 June 2024
Volitinib Antibodies: Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF...
9 KB (1,081 words) - 04:46, 16 June 2022
Volitinib Antibodies: Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF...
27 KB (3,071 words) - 04:54, 3 June 2024
Volitinib Antibodies: Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF...
45 KB (5,341 words) - 08:28, 10 June 2024
Volitinib Antibodies: Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF...
19 KB (1,435 words) - 22:27, 16 June 2024